1315 Capital
QuietFiled to raisePhiladelphia, PAHealthcare, Biotechnology, PharmaceuticalsLast fund filed 2026
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| 1315 Capital Emerging Growth & Buyout IIFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
| 1315 Capital Fund IV Family Access FundFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
| 1315 Capital IVFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
| 1315 Capital Emerging Growth & Buyout | March 2022 | $162M | $162M |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Adele Oliva | Quiet | Biotech & pharma, Healthcare services, E-commerce & marketplaces | 8 |
Classified sectors of 1315 Capital’s own portfolio companies, based on 7 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of 1315 Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Battery Ventures | 1 | Encore Dermatology |
| Causeway Media Partners | 1 | Greenbrook TMS |
| Domain Partners | 1 | Colorescience |
| Firmament | 1 |
| 51 |
| 1315 Capital III | March 2022 | $350M | $350M | 57 |
| 1315 Capital II | February 2018 | $300M | $300M | 57 |
| 0 |
| Brian Schwenk | Quiet | None listed | 0 | 0 |
| Michael Koby | Quiet | Medical devices | 2 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| TELA Bio |
| SV Life Sciences | 1 | Soluble Systems |
A shared board seat: a company where filings name a 1315 Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.